miRNA在肾细胞癌中的研究进展

Research progress of miRNA in renal cell carcinoma

肾细胞癌(RCC)约占所有成人恶性肿瘤的5%,占肾脏原发性恶性肿瘤的90%,是仅次于前列腺癌和膀胱癌的第三常见泌尿系肿瘤,死亡率极高。RCC患者对放疗、化疗均不敏感,因此目前临床上尚无辅助治疗,其主要治疗方法是手术切除。miRNA作为一种高度保守的内源性非编码单链小分子,参与细胞分化、增殖、凋亡和转移等多种细胞生物学过程,与肿瘤的发生、转移、预后等密切相关。本文就miRNA在肾细胞癌(RCC)中的最新研究进展进行综述。

Renal cell carcinoma(RCC) accounts for approximately 5% of all adult malignancies, and 90% of primary renal malignancies, which is the third most common urinary tract tumor after prostate and bladder cancers, with an extremely high mortality rate. RCC patients are not sensitive to radiotherapy and chemotherapy, so there is no adjuvant therapy in clinical practice, and the main treatment is surgical resection. As a highly conserved endogenous non-coding single-chain small molecule, miRNA is involved in a variety of cell biological processes such as cell differentiation,proliferation, apoptosis and metastasis, and is closely related to the occurrence, metastasis and prognosis of tumors. This article review the latest research progress of miRNA in RCC.